Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Temps réel estimé Cboe BZX Autres places de cotation 17:02:55 10/06/2024			Varia. 5j.	Varia. 1 janv.
64,16 ^USD	-0,83 %		+1,32 %	-20,67 %

06/06	Gilead déclare que les données relatives à l'association du bulevirtide et du PegIFN sont "supérieures" à celles de la monothérapie au bulevirtide ; le taux d'ARN du VHD indétectable est de 46%.	MT
06/06	Gilead Sciences, Inc. Annonce des données de l'étude ouverte de phase 2b MYR204	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Combination therapy may hold potential for severe viral hepatitis	06/06
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	06/06
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA	06/06
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	06/06
Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study	06/06
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	05/06
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial	05/06
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	05/06
Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis, A Rare, Chronic Inflammatory Liver Disease	05/06
Sector Update: Health Care Stocks Rise Late Afternoon	04/06
Sector Update: Health Care Stocks Rise Tuesday Afternoon	04/06
Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit	04/06
Gilead Sciences : Statement on Agreement in Principle to Resolve Federal TDF Litigation	04/06
Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma	03/06
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	03/06
Kite?S Tecartus® Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia	03/06
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma	03/06
Kite Announces Data from A Pilot Study in Collaboration with Dana-Farber Cancer Institute	03/06
Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise	03/06
Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer	02/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Autres langues

Filtres